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Abstract
Introduction: To investigate how markers of b-cell secretion (proinsulin-processing metabolites) are expressed in
rheumatoid arthritis (RA) patients and their potential relation with the insulin resistance (IR) observed in these
patients.
Methods: The 101 RA patients and 99 nondiabetic sex- and age-matched controls were included. IR by
homeostatic model assessment (HOMA2), and b-cell secretion, as measured by insulin, split and intact proinsulin,
and C-peptide levels were determined for both groups. Multiple regression analysis was performed to compare IR
between groups and to explore the interrelations between RA features, proinsulin metabolites, and IR. Data were
adjusted for glucocorticoids intake and for IR classic risk factors.
Results: Compared with controls, RA patients showed higher HOMA-IR (b coef., 0.40 (95% CI, 0.20 to 0.59); P = 0.00).
When data were adjusted for glucocorticoids intake, noncorticosteroid patients maintained a higher IR index (b, 0.14
(0.05 to 0.24); P = 0.00). Impaired insulin processing in RA patients was detected by the onset of elevated split proinsulin
levels (b, 0.70 pmol/L (0.38 to 1.02); P = 0.00). These data remained significant also when adjusted for prednisone intake
(b, 0.19 (0.00 to 0.36) pmol/L; P = 0.04). Split proinsulin-to-C-peptide ratios were higher in RA patients undergoing
corticosteroid therapy (b, 0.25 (0.12 to 0.38); P = 0.03) and were nearly significant in comparison between
noncorticosteroids patients and controls (b, 0.16 (-0.02 to 0.34); P = 0.08). Interestingly, the impact of HOMA-IR on the
ratio of intact proinsulin to C-peptide was higher in controls compared with patients (b, 6.23 (1.41 to 11.06) versus 0.43
(-0.86 to 1.71); P = 0.03).
Conclusions: b-Cell function is impaired in nondiabetic and in RA patients not taking corticoids by a mechanism
that seems to be, at least in part, independent of IR.
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, inflam-
matory disorder of unknown etiology that, if left uncon-
trolled, may lead to the destruction and deformity of
joints because of the erosion of cartilage and bone.
Although a higher prevalence of traditional cardiovascu-
lar risk factors may be present in patients with RA than
in the general population, epidemiologic data suggest
that RA is an independent risk factor for cardiovascular
disease and may be a major contributor to increased
patient mortality [1,2].
Several reports have linked clinical RA activity with a
reduction in peripheral insulin sensitivity [3-7]. Insulin
resistance (IR) refers to a state in which a given concentra-
tion of insulin is associated with a subnormal glucose
response [8]. IR is the primary defect underlying the devel-
opment of type 2 diabetes mellitus and is a key component
defining the metabolic syndrome, a constellation of
abnormalities including obesity, hypertension, glucose
intolerance, and dyslipidemia that may eventually lead to
cardiovascular disease. As IR has recently been associated
with states of low-grade inflammation, it is now believed
that inflammation might contribute to its development
[9]. Similarly, IR is now additionally recognized as a com-
ponent of several disorders in which a chronic inflamma-
tory state is present, such as RA [10].
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A complex network of inflammatory cytokines, adipo-
cytokines, transcription factors, receptor molecules, and
acute-phase reactants are involved in the development of
IR. Both peripheral insulin action and insulin secretion
have been shown to be impaired in IR states, leading to
an increased proportion of insulin precursor, proinsulin
[11]. These findings are supported by the fact that inter-
mediate proinsulin products like des-31,32 or des-62,64
proinsulin are elevated in IR and diabetes patients
[12,13], showing that the processing of proinsulin to
insulin in b cells is impaired.
Previous studies that have examined insulin sensitivity
and b-cell function in RA have relied solely on fasting
parameters, such as HOMA (Homeostatic Model Assess-
ment)-IR and HOMA%B. Although these model-derived
indices have been well validated, they provide no infor-
mation about proinsulin processing or insulin secretion
by b cells. In this regard, disproportionate hyperproinsu-
linemia as an indicator of b-cell dysfunction has not been
explored in RA. The aim of this study was to investigate
b-cell function (secretion) in RA patients and its potential
relation with the IR observed in these patients.
Materials and methods
Study participant
Two hundred subjects, 101 RA patients and 99 age- and
sex-matched controls, were recruited for this cross-sec-
tional study. These RA patients, men and women ages 18
or older, were diagnosed by a rheumatologist as having
fulfilled 2010 ACR/EULAR diagnostic criteria [14]. For
inclusion in the present study, RA disease duration was
required to be ≥ 1 year. To minimize the potential effects
of tumor necrosis factor (TNF) blockers on IR [5], RA
patients undergoing TNF-antagonist therapy were not
included in the present study. However, because corticos-
teroids are often used in the management of RA, patients
taking prednisone or an equivalent dose (12 mg/day or
less) were not excluded. Nevertheless, we established two
groups within the cohort of RA patients; those receiving
prednisone therapy, which included subjects then being
treated with such drugs or who had been taking corticos-
teroids within 3 months before the onset of the study,
and those not taking corticosteroids, which included RA
patients who had not received corticosteroids during the
12 months before recruitment. The glucocorticoid dose
was measured as the equivalent prednisone dose admi-
nistered during the previous 3 months (milligrams per
day). Patients and controls with diabetes mellitus were
not included in the study. Therefore, none of the patients
or controls was receiving glucose-lowering drugs or insu-
lin therapy. All patients and controls had a glucemia < 7
mmol/L. Patients and controls were excluded if they had
a history of myocardial infarction, angina, stroke, a glo-
merular filtration rate < 60 ml/min/1.73 m2, a history of
cancer, or any other chronic disease, or evidence of infec-
tion. None of the controls was receiving corticosteroid
treatment. The study protocol was approved by the insti-
tutional review committee at Hospital Universitario de
Canarias (Spain), and all subjects provided written
informed consent.
Data collection
Patient surveys for both the RA and control groups were
identical, except that subjects with RA were asked addi-
tional questions pertaining to their disease. Subjects com-
pleted a cardiovascular risk factor and medication use
questionnaire and underwent a physical examination to
assess their anthropometrics and blood pressure. Medical
records were reviewed to ascertain the specific diagnosis
and medication. Weight was assessed to the nearest 100
g with the participant standing on a portable digital scale
(SECA, Hamburg, Germany). Standing height was mea-
sured to the nearest 1 cm with a stadiometer (SECA).
Waist circumference was measured at the smallest cir-
cumference between the rib cage and the iliac crest,
while the subject was in a standing position. The hip cir-
cumference was measured at the widest circumference
between the waist and thighs. The waist-to-hip ratio also
was estimated. In patients with RA, disease activity was
measured by using the Disease Activity Score (DAS28) in
28 joints [15], whereas disease disability was determined
by using the Health Assessment Questionnaire (HAQ)
[16]. The metabolic syndrome was defined based on the
2005 National Cholesterol Education Program (Adult
Treatment Panel (ATP) III) criteria) [17].
Assessments
The homeostatic model assessment (HOMA) method was
performed to determine IR; specifically, in this study, we
used HOMA2: the updated-computer HOMA model
[18-20]. In brief, this method consists of a structural com-
puter model of the glucose-insulin feedback system in a
homeostatic (overnight-fasted) state. The model comprises
a number of nonlinear empirical equations (and precludes
an exact algebraic solution), which describes the functions
of organs and tissues involved in glucose regulation. This
model can be used to determine insulin sensitivity (%S)
and b-cell function (%B) from paired fasting plasma glu-
cose and specific insulin, or C-peptide concentrations
across a range of 1 to 2,200 pmol/L for insulin and 1 to 25
mmol/L for glucose. In our study, we used C-peptide to
calculate b-cell function, because the former is a marker
of secretion. In addition, we used insulin data to calculate
%S (because HOMA-%S is derived from glucose disposal
as a function of insulin concentration). This computer
model provides an insulin-sensitivity value expressed as
HOMA2-%S (where 100% is normal). HOMA2-IR (insulin
resistance index) is simply the reciprocal of %S.
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Insulin (Architect Abbott, 2000I) and C-peptide (Immu-
lite 2000, Siemens) were determined with chemilumines-
cent immunometric assays. Intact proinsulin was assessed
through ELISA (Millipore, Billerica, MA, USA). This
ELISA does not cross-react with human insulin, and the
presence of insulin (up to 208 μU/ml) in serum does not
interfere with the assay results. The kit has no cross-reac-
tivity with the major species of proinsulin metabolites, des
(31,32) proinsulin, and cross-reacts only weakly with the
minor intermediate des(64,65) proinsulin (interassay preci-
sion, 3.3% to 9.0%; intraassay, 0.4% to 7.7%). Total (split)
proinsulin was detected with ELISA (Millipore). This kit
has 100% cross-reactivity with intact human proinsulin
and its major processed intermediate, des(31,32) proinsu-
lin, and 81% cross reactivity with its processed intermedi-
ate des(64,65) proinsulin. Human insulin (up to 200
μU/ml) and human C-peptide (up to 10 ng/ml) do not
interfere with the assay results. Precision was estimated as
interassay, 2.9% to 8.3%; intraassay, 0.8% to 8.5%. A split
proinsulin to C-peptide ratio was used as a surrogate mar-
ker of b-cell function [21]. Standard techniques were used
to measure plasma glucose, C-reactive protein (CRP), the
Westergren erythrocyte sedimentation rate (ESR), and
serum lipids.
Statistical analysis
On the basis of previously published findings [13,21], we
assumed a normal intact proinsulin to C-peptide ratio
of 10% in controls and 14% in patients with insulin. Pro-
ceeding with these assumptions, by using a 1:1 relation,
and according to a Student t test with an a level of 0.05
and a b level of 0.15, we estimated that we would need
to enroll 184 subjects: 92 patients and 92 controls.
Demographic and clinical characteristics shown in Table
1 were compared between patients with RA and con-
trols by using c2 tests for categoric variables or Student
t tests for continuous variables (data described as mean
± standard deviation). For noncontinuous variables,
either a Mann-Whitney U test was performed, or a loga-
rithmic transformation was made, and data were
expressed as a median (interquartile range). Association
of insulin sensitivity and b-cell function with clinical
features of RA, as well as comparisons between RA
patients and controls, were conducted through multi-
variate analysis, adjusting for factors known to be asso-
ciated with IR. Two different models were defined for
the results obtained from these analyses. An unadjusted
model in which RA features and metabolic syndrome
factors were associated through univariate analysis, and
an adjusted model in which RA features were correlated
with insulin-sensitivity parameters after adjustment for
these classic risk factors through multiple regression
also were carried out. A dissimilar impact of HOMA-IR
on proinsulin metabolites in patients and controls was
established, adding an interaction term, by using multi-
variate regression analysis. All analyses used a 5% two-
sided significance level and were performed by using
SPSS software, version 19 (IBM, Chicago, IL, USA). A P
value < 0.05 was considered statistically significant.
Results
Characteristics of the participants
A total of 200 participants, 101 RA patients and 99 con-
trols, with a mean (± standard deviation) age of 55.2 ±
10.0 years and 55.1 ± 10.6 years (P = 0.90), respectively,
were included in this study. The demographic and dis-
ease-related characteristics of the participants are shown
in Table 1. Patients in our series had moderate-active dis-
ease as shown by DAS28 (3.99 ± 1.41). Half (54.5%) were
taking prednisone (an average dose of 6.2 ± 2.5 mg/day
during the last year). No differences were found between
patients and controls in regard to BMI, waist circumfer-
ence, hypertension, or metabolic syndrome. As expected,
analyses of ESR and CRP values revealed statistically sig-
nificant differences between controls and patients. Apart
from an increased frequency of positive rheumatoid fac-
tor among RA patients receiving corticosteroid therapy,
compared with those not taking corticosteroids (78% ver-
sus 38%; P = 0.00), no significant differences between the
two subgroups of RA patients were observed in terms of
disease duration, activity scores, age, or BMI.
Insulin-resistance indices
Insulin-resistance indices are shown in Table 2. RA
patients had a higher HOMA-IR index (log b coefficient,
0.40 (95% CI, 0.20 to 0.59); P = 0.00) and elevated b-cell
function, HOMA%B- (log b coef. 22% (95% CI, 5 to 39);
P = 0.01) with respect to controls. When RA patients were
divided into prednisone intake or non-intake groups, non-
corticoids RA patients showed a statistically significantly
higher rate of IR compared with controls (log b coef. 0.14
(0.05 to 0.24); P = 0.00). Similar results were found with
regard to b-cell function, with an elevated HOMA%B in
noncorticoid patients when compared with controls (log b
coef. 11% (95% CI, 2 to 19); P = 0.02).
As is evident in Table 2, in the multiple regression ana-
lysis, none of the IR indices correlated with such RA fea-
tures as disease duration, rheumatoid factor positivity,
ESR, C-reactive protein, DAS 28 or HAQ scores, predni-
sone doses (milligrams per day during the 3 previous
months), current prednisone or DMARD intake (%S are
not shown because they simply represent the reciprocal of
IR). This lack of any correlation remained nonsignificant
when data were adjusted for those classic risk factors asso-
ciated with IR such as sex, age, BMI, or hypertension
(adjusted model). Only C-reactive protein proved inversely
related with IR (P = 0.05), although this was not main-
tained when adjusted for the classic IR risk factors.
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As shown in Table 2, although classic IR triggers (BMI,
waist circumference, and hypertension) were strongly
associated with IR indices in RA patients, these classic
risk factors made a dissimilar impact on IR indexes in
patients and controls. In both RA and control groups,
higher BMI, waist circumference, hypertension, and/or
male sex were each generally associated with worse IR
indexes (data not shown). However, the impact of BMI
on the IR index in RA patients was more important than
in controls (b coefficient 0.06 (0.03 to 0.10) versus 0.03
(0.01 to 0.05), P = 0.00). In contrast, the impact of waist
circumference seemed more important in controls than
in RA patients (b coef. 0.03 (0.01 to 0.04) versus 0.02
(0.01 to 03); P = 0.05), although statistic significance was
not reached.
b-Cell function markers and proinsulin-processing
metabolites
Independent of prednisone intake, C-peptide levels were
higher in non-steroid-taking patients compared with con-
trols (logC-peptide, b coef. 0.20 nmol/L (0.02 to 0.38); P =
0.03). Insulin levels were also higher in noncorticoids RA
patients than in those taking steroids. Conversely, neither
insulin nor C-peptide correlated with prednisone dosing
(milligrams per day) during the 3 previous months.
Markers of b-cell dysfunction proved different between
controls and patients (Figure 1). In this regard, split
proinsulin, which expresses intact human proinsulin, as
well as its major intermediate metabolites, des(31,32)
proinsulin, and des(64,65) proinsulin, was higher in RA
patients, (logSplit insulin, b coef. 0.70 pmol/L (0.38 to
1.02); P = 0.00), even when adjusting for corticosteroid
intake, sex, BMI, and age. The split proinsulin-to-C-
peptide ratio was higher in RA patients undergoing corti-
costeroid therapy (b coef. 0.25 pmol/L (0.12 to 0.38); P =
0.03) and nearly reached significance in the comparison
between noncorticoids patients and controls (b coef.,
0.16 pmol/L (-0.02 to 0.34); P = 0.08); Figure 1 illustrates
these differences.
Measurements of intact proinsulin levels showed similar
results. Generally, patients expressed higher levels (b coef.,
0.81 pmol/L (0.13 to 1.46); P = 0.02), and these data
remained significant when adjusted for corticoids intake
(Table 3). The intact proinsulin-to-C-peptide ratio was
higher in patients compared with controls (b coef., 0.55
pmol/L (0.05 to 1.05); P = 0.03). When these data were
Table 1 Demographics and disease-related characteristics of patients and controls
Rheumatoid arthritis (n = 101) Controls (n = 99) Pa
GC-RA (n = 46) GC+RA (55) Pb
Age, years 55.2 ± 10.0 53.0 ± 10.1 57.1 ± 9.7 0.04a 55.1 ± 10.6 0.90
Female, n (%) 86 (85) 38 (67) 48 (87) 0.51 90 (91) 0.21
Body mass index, kg/m2 29.5 ± 5.9 27.8 ± 4.8 30.0 ± 6.6 0.18 29.5 ± 5.4 0.59
Hip circumference, cm 106 (99-118) 105 (97-115) 109 (99-118) 0.17 102 (98-110) 0.23
Waist circumference male, cm 106 ± 17 105 ± 12 107 ± 22 0.79 100 ± 12 0.57
Waist circumference female, cm 96 ± 15 92 ± 14 98 ± 15 0.13 91 ± 11 0.12
Waist-to-hip ratio 0.90 (0.85-0.94) 0.89 (0.83-0.94) 0.90 (0.86-0.94) 0.34 0.86 (0.80-0.92) 0.71
Hypertension, n (%) 36 (38) 14 (25) 22 (40) 0.51 31 (31) 0.34
Statins intake, n (%) 29 (30) 13 (23) 16 (29) 0.78 28 (28) 0.77
Metabolic syndrome, n (%) 32 (37) 15 (27) 17 (31) 0.96 18 (18) 0.11
ESR, mm/h 25 (16-39) 25 (15-41) 26 (18-39) 0.70 18 (13-25) 0.00a
CRP, mg/dl 3.8 (1.4-9.4) 4.5 (1.3-13.7) 3.2 (1.6-9.0) 0.59 2.0 (0.9-4.7) 0.00a
Cholesterol, mg/dl 210 ± 40 203 ± 30 216 ± 46 0.18 207 ± 39 0.62
Triglycerides, mg/dl 118 (85-151) 110 (81-139) 121 (91-152) 0.28 102 (69-133) 0.00a
HDL cholesterol, mg/dl 59 ± 15 58 ± 14 60 ± 16 0.48 56 ± 14 0.13
LDL cholesterol, mg/dl 127 ± 33 127 ± 28 127 ± 37 0.89 129 ± 34 0.62
Disease duration, years 7.5 ± 5.8 8.7 ± 4.5 6.2 ± 6.8 0.08
DAS28-ESR 3.99 ± 1.41 4.11 ± 1.56 3.18 ± 1.27 0.45
HAQ 0.61 (0.24-1.28) 0.69 (0.13-1.37) 0.55 (0.2-1.23) 0.92
Positive rheumatoid factor, n (%) 64 (65) 21 (38) 43 (78) 0.00a
Current nonbiologic DMARD, n (%) 88 (87) 41 (73) 47 (85) 0.58
Current prednisone, n (%) 55 (54.5)
Prednisone, average mg/day/3 months 6.24 ± 2.54
aComparison between controls and patients; P value < 0.05. bComparison between not-taking-corticoids and taking-corticoids patients. Data expressed as mean
(± standard deviation) or median (interquartile range). Dichotomous variables are expressed as n and percentage. CRP, C-reactive protein; DAS28, Disease Activity
Score; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; GC-RA, RA patients not taking corticosteroids; GC+RA, RA patients
taking prednisone. HAQ, Health Assessment Questionnaire; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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RA versus controls (b 95% CI for RA, 101, and controls, 99) 0.40 (0.20-0.59) 0.00
GC-RA versus controls (b 95% CI for RA, 56, and controls, 99) 0.14 (0.05-0.24) 0.00
GC+RA versus controls (b 95% CI for RA, 55, and controls, 99) 0.17 (0.10-0.24) 0.00
RA features
Disease duration -0.02 (-0.06-0.01) 0.19 -0.01 (-0.05-0.03) 0.59
RF positivity 0.00 (-0.39-0.39) 0.99 -0.15 (-0.54-0.24) 0.86
ESR -0.00 (-0.01-0.01) 0.66 -0.01 (-0.02-0.00) 0.26
CRP -0.01 (-0.02-0.00) 0.05 -0.01 (-0.02-0.00) 0.07
Current prednisone 0.23 (-0.14-0.60) 0.22 0.04 (-0.32-0.40) 0.81
Prednisone, mg/day/previous 3 months 0.01 (-0.18-0.20) 0.94 -0.23 (-0.46-0.01) 0.47
HAQ -0.01 (-0.30-0.29) 0.97 0.12 (-0.18-0.41) 0.44
DAS28 -0.00 (-0.14-0.13) 0.95 -0.05 (-0.17-0.07) 0.40
Current nonbiologic DMARD -0.28 (-1.35-0.79) 0.60 0.08 (-0.67-0.82) 0.83
Classic IR risk factors
Sex -0.24 (-0.76-0.27) 0.35
Age 0.00 (-0.02-0.02) 0.83
BMI 0.06 (0.03-0.10) 0.0a
Waist circumference 0.02 (0.01-0.03) 0.00a
Triglycerides 0.00 (0.00-0.01) 0.07
Hypertension 0.48 (0.11-0.86) 0.01a
b-cell function (logHOMA%B)
RA versus controls (b 95% CI for RA, 101, and controls, 99) 22 (5-39) 0.01
GC-RA versus controls (b 95% CI for RA, 56, and controls, 99) 11 (2-19) 0.02
GC+RA versus controls (b 95% CI for RA, 55, and controls, 99) 8 (0-15) 0.05
RA features
Disease duration 2 (-1-4) 0.27 1 (-2-4) 0.40
RF positivity 10 (21-42) 0.52 11 (-19-41) 0.46
ESR 0 (-1-1) 0.52 0 (-1-1) 0.61
CRP 1 (-2-1) 0.32 0 (-1-1) 0.40
Current prednisone 1 (-28-31) 0.93 3 (-26-32) 0.85
Prednisone, mg/day/previous 3 months 2 (-15-18) 0.83 10 (-8-21) 0.36
HAQ -3 (-27-21) 0.83 3 (-20-26) 0.81
DAS28 -1 (-12-10) 0.81 -0 (-11-10) 0.95
Current nonbiologic DMARD -16 (110-79) 0.74 -15 (-100-71) 0.73
Classic IR risk factors
Sex -52 (-92–12) 0.0a
Age -1 (-3-0) 0.06
BMI 2 (-1-5) 0.16
Waist circumference 0 (-1-1) 0.67
Triglycerides 0 (-0-0) 0.90
Hypertension 10 (-21-41) 0.53
HOMA-IR and HOMA%B are considered dependent variables and were log transformed. b-coefficients are expressed log transformed. Β-coefficient refers to changes in
insulin resistance (IR) or b-cell function (%B) outcome per unit increase in the indicated characteristic. Sex refers to the change from female to male; current prednisone
to the change from not taking corticoids to taking corticosteroids treatment, and RF positivity, to the change from negative to positive rheumatoid factor. Adjusted
model represents a model in which RA features are adjusted for the classic risk factors of the previous model with P < 20 (BMI, and hypertension in the IR model; and
sex, age, and BMI for the %B model). See Table 1 for abbreviations and units. Significant associations (P < 0.05) are depicted in bold
Ferraz-Amaro et al. Arthritis Research & Therapy 2013, 15:R17
http://arthritis-research.com/content/15/1/R17
Page 5 of 10
adjusted for steroids consumption, statistical significance
was not reached, although patients showed superior ratios.
RA features like ESR, CRP, DAS28, HAQ, and rheu-
matoid factor positivity were not associated with b-cell
marker or proinsulin-processing metabolite levels (Table
3). Only disease duration showed a significant negative
association with split proinsulin and split proinsulin-to-
C-peptide ratios. Similarly, current prednisone intake (as
a dichotomous variable) was associated with a higher
split insulin-to-C-peptide ratio.
A different relation between HOMA-IR and proinsulin
metabolites was found in patients when compared with
controls. Table 4 shows that controls generally expressed
higher b coefficients of proinsulin metabolites over the
same increase in the IR index. Thus, the impact of IR on
the intact proinsulin-to-C-peptide ratio was higher in
controls than in RA patients (6.23 (95% CI, 1.41 to 11.06)
versus 0.43 (-0.86 to 1.71); P = 0.03); this association was
not found in the split proinsulin/C-peptide ratio. When
patients were divided into those taking corticoids and
those who do not, no differences were found in the
relation between HOMA-IR and split or intact proinsulin
levels (Table 4).
Discussion
IR is characterized by hyperglycemia and relative impair-
ment of insulin secretion. This condition has been
described in RA patients, with its severity proving propor-
tional to the degree of inflammatory activity [10,22,23],
and this holds true for other inflammatory chronic dis-
eases as well [24]. Understanding its pathogenesis is com-
plicated because patients typically have varying degrees of
both peripheral resistance and insulin deficiency. HOMA
indices, although widely used, do not account for the dif-
ferences observed in hepatic and peripheral insulin sensi-
tivity, or for the variations seen in insulin secretion. For
this reason, we decided to evaluate RA-related IR more
accurately by measuring intact proinsulin, as well as its
metabolites, as an expression of islet b-cell function. Our
study suggests that the processing of proinsulin to insulin
in b cells is impaired in nondiabetic noncorticoids RA
patients. To our knowledge, this is the first study that has






































































Figure 1 Intact and split proinsulin in RA patients and controls. Left graph (data plot on left axes) shows absolute values of intact proinsulin
(black), split proinsulin (gray), and total insulin (white) in controls, non-glucocorticoids rheumatoid arthritis patients (GC-RA), rheumatoid arthritis
patients taking glucocorticoids (GC+RA), and total rheumatoid arthritis patients (Total RA). Right graph (data plot on right axes) shows split
proinsulin to C-peptide ratio (%) in the same groups. Significant P values are detailed.
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Table 3 Associations of proinsulin-processing metabolites with RA features
Β-coefficient (95% CI)
Insulin and C-peptide (dependent variables)
logInsulin pM P logC-peptide P
RA versus controls (b 95% CI for RA, 101, and controls, 99) 0.39 (0.14-0.64) 0.00 0.61 (0.32-0.91) 0.00
GC-RA versus controls (b 95% CI for RA, 56, and controls, 99) 0.14 (0.01-0.27) 0.04 0.20 (0.02-0.38) 0.03
GC+RA versus controls (b 95% CI for RA, 55, and controls, 99) 0.15 (0.06-0.25) 0.00 0.29 (0.17-0.40) 0.00
RA patients features (b 95% CI for RA, 101)
Disease duration -0.79 (-3.32-1.74) 0.54 -0.01 (-0.02-0.00) 0.07
RF positivity -10. 9 (-46.9-25.2) 0.99 0.03 (-0.06-0.12) 0.51
ESR -0.50 (-1.49-0.50) 0.33 -0.00 (-0.01-0.00) 0.12
CRP -0.21 (-1.34-0.91) 0.03 0.00 (-0.00-0.00) 0.65
Current prednisone 0.13 (-0.23-0.48) 0.48 0.10 (0.01-0.18) 0.02
Prednisone, mg/day/previous 3 months -3.28 (-22.36-15.80) 0.25 -0.02 (-0.05-0.02) 0.16
HAQ 3.03 (-20.32-26.37) 0.63 -0.02 (-0.09-0.05) 0.69
DAS28 -0.21 (-10.89-10.49) 0.67 0.00 (-0.03-0.03) 0.99
Current nonbiologic DMARD 23.58 (-63.53-110.68) 0.79 0.05 (-0.13-0.23) 0.61
logIntact proinsulin (dependent variable)
Intact proinsulin p Intact proinsulin/C-peptide ratio p
RA versus controls (b 95% CI for RA, 101, and controls, 99) 0.81 (0.13-1.46) 0.02 0.55 (0.05-1.05) 0.03
GC-RA versus controls (b 95% CI for RA, 56, and controls, 99) 0.34 (0.05-0.62) 0.02 1.65 (-0.06-3.35) 0.06
GC+RA versus controls (b 95% CI for RA, 55, and controls, 99) 0.24 (0.05-0.43) 0.01 0.14 (-0.04-0.33) 0.13
RA patients features (b 95% CI for RA, 101)
Disease duration 0.03 (-0.46-0.51) 0.83 0.13 (-0.45-0.71) 0.96
RF positivity 3.4 (0.25-6.51) 0.11 3.45 (-0.34-7.25) 0.15
ESR -0.03 (-0.12-0.06) 0.92 0.01 (-0.11-0.10) 0.62
CRP 0.02 (-0.07-0.12) 0.50 0.03 (-0.08-0.14) 0.47
Current prednisone -0.07 (-0.73-0.59) 0.83 -1.40 (-5.30-2.50) 0.48
Prednisone. mg/day/previous 3 months -0.11 (-1.86-1.65) 0.82 -0.05 (-1.83-1.73) 0.63
HAQ 0.62 (-2.13-3.37) 0.75 1.23 (-1.99-4.46) 0.85
DAS28 0.49 (-0.74-1.72) 0.65 0.39 (-1.03-1.82) 0.68
Current nonbiologic DMARD 2.93 (-7.52-13.34) 0.91 3.40 (-7.45-14.26) 0.96
logSplit proinsulin (dependent variable)
Split proinsulin P Split proinsulin/C-peptide ratio P
RA versus controls (b 95% CI for RA, 101, and controls, 99) 0.70 (0.38-1.02) 0.00 0.57 (0.30-0.88) 0.00
GC-RA versus controls (b 95% CI for RA, 56, and controls, 99) 0.19 (0.00-0.36) 0.04 0.16 (-0.02-0.34) 0.08
GC+RA versus controls (b 95% CI for RA, 55, and controls, 99) 0.33 (0.20-0.45) 0.00 0.25 (0.12-0.38) 0.00
RA patients features (b 95% CI for RA, 101)
Disease duration -1.58 (-2.84-0.31) 0.01 -1.82 (-3.48-0.17) 0.02
RF positivity 2.83 (-8.33-13.98) 0.60 5.11 (-8.54-18.76) 0.67
ESR 0.08 (-0.39-0.22) 0.60 -0.02 (-0.39-0.35) 0.93
CRP 0.16 (-0.18-0.51) 0.42 0.20 (-0.23-0.62) 0.33
Current prednisone 0.57 (0.18-0.96) 0.00 0.41 (0.05-0.76) 0.03
Prednisone. mg/day/previous 3 months -1.04 (-6.99-4.91) 0.98 -0.14 (-6.50-6.22) 0.71
HAQ -3.17 (-11.15-4.81) 0.11 -0.35 (-10.84-10.14) 0.43
DAS28 1.11 (-2.89-5.11) 0.82 -1.79 (-3.01-6.67) 0.67
Current nonbiologic DMARD 15.28 (-15.93-46.49) 0.83 15.43 (-17.36-48.23) 0.73
All b coefficients are adjusted for sex, age, and body mass index. All dependent variables are considered log transformed. Rheumatoid factor (RF) positivity,
current prednisone and current nonbiologic DMARD are consider dichotomous variables. For abbreviations and units, see Table 1. Significant associations
(P < 0.05) are depicted in bold
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examined insulin resistance in RA with regard to these
insulin-processing metabolites.
Insulin production in normal subjects involves clea-
vage of insulin from proinsulin; 10% to 15% of secreted
insulin comprises proinsulin and/or its conversion inter-
mediates. In contrast, the proportion of immunoreactive
insulin that is proinsulin in type 2 diabetes increases
considerably in the basal state. In our study, we detected
an increase in intact and split proinsulin in RA patients
with respect to healthy controls, a difference that was
not corticoid mediated. The reasons for these increased
levels of proinsulin and its related metabolites are likely
multifactorial. It is possible that the IR recorded in the
RA patients in our study may have arisen from ineffi-
cient proinsulin processing within the b-cell secretory
granules or from the premature release of proinsulin as
a result of increased demand for insulin due to systemic
inflammation [25].
Elevations in the ratio of proinsulin to insulin, as well
as in absolute proinsulin concentrations adjusted for
fasting insulin, have been postulated as early markers of
b-cell dysfunction [26]. However, proinsulin/C-peptide
ratios have been shown to be a stronger predictor of
diabetes [21]. These findings support the use of C-pep-
tide as the best denominator for proinsulin ratios,
because it more accurately reflects the degree of dispro-
portional hyperproinsulinemia, which is in agreement
with our findings that show higher and significant split
proinsulin/C-peptide ratios in RA patients compared
with controls. Some evidence links b-cell function and
inflammation. Proinflammatory cytokines relevant to the
pathogenesis of RA, such as interleukin-1b and tumor
necrosis factor a, have been implicated in both the
functional inhibition [27] and apoptosis induction [28]
of islet b cells. These and other findings [29,30] suggest
that inflammatory mediators might play a role in the b-
cell dysfunction that we observed in RA patients.
It is difficult to separate the IR that occurs peripher-
ally from that which arises because of, or after, b-cell
damage. It remains unknown whether b-cell failure or a
peripheral compensatory-like mechanism occurs first;
however, once peripheral organs mount a resistance to
insulin, pancreatic cell damage occurs. Interestingly, we
found that when a similar increase in IR occurred, the
intact proinsulin/C-peptide ratio was higher in controls
than in RA patients. This could signify that the b-cell
dysfunction observed in RA patients is at least in part
independent of the severity of IR and allows the possibi-
lity that other factors, including inflammation, might be
involved. Our data regarding IR levels in RA patients
are in agreement with previous studies [4,22,23,31-33].
Surprisingly, in our series, however, we have not been
able to find an association between RA disease activity
scores, ESR, or CRP with IR, a finding that is not in
agreement with the current evidence [10,22,23].
In the multiple regression analysis models, we found
that abdominal obesity and BMI correlate with IR
indices in both RA patients and controls. Abnormal
body composition is a feature observed in RA, and the
amount and distribution of fat and lean mass have
important implications for IR [34]. Interestingly, accord-
ing to our results, it seems that the impact of BMI on
IR was higher in RA patients than in controls.
Because glucorticoids are an important factor affecting
the development of hyperglycemia, and as they are
usually prescribed to RA patients, corticosteroid intake
and doses were examined in our study. In this regard,
and in accordance with multiple regression analysis, we
found that prednisone intake (as a dichotomous vari-
able) or average prednisone dosing (milligrams per day
during the 3 months prior) was not associated with IR
indices in the intragroup of RA patients comparison,
except for its relation with C-peptide and split proinsu-
lin. Thus, our data are in keeping with previous reports
contending that the use of high-dose glucocorticoids
often results in hyperglycemia. However, it has been
suggested that a low cumulative corticosteroid dose in
RA patients may lead to improvement in b-cell function,
Table 4 Different relation between HOMA-IR index and proinsulin metabolites in controls and patients.
b coefficient (95% CI)
Intact proinsulin Intact proinsulin/ Split proinsulin Split proinsulin/
C-peptide ratio C-peptide ratio
HOMA-IR index
Controls 4.02 (0.66-7.36) 6.23 (1.41-11.06) 10.95 (3.22-18.17) 14.84 (3.99-25.70)
Patients 0.97 (-0.11-2.06) 0.43 (-0.86-1.71) 6.98 (3.44-10.52) 5.83 (1.40-10.25)
P valuea 0.36 0.03 0.47 0.23
RA on GC 1.28 (-0.42-2.98) 0.39 (-1.66-2.44) 6.94 (3.38-10.50) 5.37 (1.06-9.69)
RA non on GC 0.74 (-0.82-2.28) 5.55 (-1.26-2.36) 4.95 (-1.29-11.18) 3.70 (-4.13-11.72)
P valueb 0.63 0.90 0.57 0.72
P value represents the comparison of b coefficient between controls and patients (a) and between RA on GC and RA not taking GCs (b) when interaction
“HOMAIR × disease” is included in the regression model. HOMA-IR index is considered an independent variable, and proinsulin metabolites as dependent
variables. Significant associations (P < 0.05) are depicted in bold
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as estimated by HOMA-%B [23]. For example, Toms
et al. [35] did not find any association between corticos-
teroid use and the presence of metabolic syndrome in
RA patients. In any case, the mechanisms associated
with the development of metabolic syndrome related to
corticosteroid use in RA need further elucidation.
We acknowledge that some limitations exist in our
study. Both patients and controls exhibited high BMI,
and thus IR indices and proinsulin levels might have
been overestimated, particularly in controls. However,
RA is a disease that is frequently associated with changes
in BMI, and RA patients frequently have a high BMI. Sec-
ond, as discussed earlier, corticosteroids exert pleiotropic
metabolic effects that may be difficult to interpret in a
chronic inflammatory disease setting, such as occurs in
RA. This could therefore be likened to a double-edged
sword, in that whereas corticosteroids have been asso-
ciated with IR, at the same time, they confer beneficial
antiinflammatory effects.
Conclusions
In the present study, we observed that b-cell function is
impaired in RA patients. Not only may the mechanisms
leading to this condition be related to the disease itself,
but they may also be different from those found in other
IR-related conditions, such as diabetes mellitus and
obesity.
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